DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,200 filers reported holding DANAHER CORPORATION in Q1 2018. The put-call ratio across all filers is 0.54 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $44,288,579 | +64.8% | 178,511 | +59.4% | 0.12% | +43.2% |
| Q2 2023 | $26,880,000 | -35.0% | 112,000 | -31.8% | 0.08% | -9.0% |
| Q1 2023 | $41,384,968 | +155.6% | 164,200 | +169.2% | 0.09% | +93.5% |
| Q4 2022 | $16,190,620 | -12.9% | 61,000 | -15.3% | 0.05% | -19.3% |
| Q3 2022 | $18,597,000 | +78.9% | 72,000 | +75.6% | 0.06% | +72.7% |
| Q2 2022 | $10,394,000 | -29.9% | 41,000 | -18.8% | 0.03% | -29.8% |
| Q1 2022 | $14,819,000 | -76.5% | 50,520 | -73.7% | 0.05% | -77.5% |
| Q4 2021 | $63,173,000 | -27.5% | 192,009 | -32.9% | 0.21% | -33.0% |
| Q3 2021 | $87,151,000 | +325.7% | 286,266 | +275.3% | 0.31% | +294.9% |
| Q2 2021 | $20,472,000 | +74.9% | 76,284 | +46.7% | 0.08% | +51.9% |
| Q1 2021 | $11,706,000 | -43.7% | 52,006 | -44.4% | 0.05% | -42.2% |
| Q4 2020 | $20,786,000 | +584.4% | 93,570 | +563.6% | 0.09% | +462.5% |
| Q3 2020 | $3,037,000 | -75.5% | 14,100 | -79.9% | 0.02% | -79.7% |
| Q2 2020 | $12,413,000 | +32.1% | 70,200 | +3.4% | 0.08% | +8.2% |
| Q1 2020 | $9,398,000 | +47.6% | 67,900 | +63.6% | 0.07% | +65.9% |
| Q4 2019 | $6,369,000 | +175.7% | 41,492 | +159.3% | 0.04% | +120.0% |
| Q3 2019 | $2,310,000 | +124.5% | 16,000 | +122.2% | 0.02% | +122.2% |
| Q2 2019 | $1,029,000 | -80.9% | 7,200 | -82.4% | 0.01% | -78.6% |
| Q1 2019 | $5,386,000 | +8.2% | 40,800 | -15.5% | 0.04% | +13.5% |
| Q4 2018 | $4,977,000 | -6.6% | 48,266 | -1.6% | 0.04% | +32.1% |
| Q3 2018 | $5,331,000 | -2.4% | 49,059 | -11.4% | 0.03% | -3.4% |
| Q2 2018 | $5,463,000 | +14.6% | 55,357 | +13.7% | 0.03% | +7.4% |
| Q1 2018 | $4,768,000 | -8.7% | 48,701 | -13.5% | 0.03% | +3.8% |
| Q4 2017 | $5,224,000 | +23.6% | 56,282 | +14.3% | 0.03% | +30.0% |
| Q3 2017 | $4,225,000 | +21.4% | 49,239 | +19.3% | 0.02% | -4.8% |
| Q2 2017 | $3,481,000 | -13.9% | 41,268 | -12.7% | 0.02% | -25.0% |
| Q1 2017 | $4,045,000 | -73.7% | 47,256 | -76.1% | 0.03% | -74.1% |
| Q4 2016 | $15,391,000 | +8.1% | 197,700 | +8.9% | 0.11% | +16.1% |
| Q3 2016 | $14,235,000 | -25.0% | 181,600 | -3.3% | 0.09% | -25.6% |
| Q2 2016 | $18,968,000 | -26.6% | 187,800 | -31.1% | 0.12% | -45.2% |
| Q1 2016 | $25,847,000 | +90.5% | 272,500 | +86.5% | 0.23% | +72.7% |
| Q4 2015 | $13,571,000 | +209.8% | 146,116 | +184.3% | 0.13% | +230.0% |
| Q3 2015 | $4,380,000 | -94.5% | 51,386 | -94.5% | 0.04% | -94.9% |
| Q2 2015 | $79,559,000 | +2280.6% | 929,519 | +2260.4% | 0.79% | +2217.6% |
| Q1 2015 | $3,342,000 | -45.2% | 39,380 | -44.7% | 0.03% | -38.2% |
| Q4 2014 | $6,103,000 | +8.2% | 71,204 | -4.0% | 0.06% | -16.7% |
| Q3 2014 | $5,638,000 | +783.7% | 74,173 | +816.6% | 0.07% | +633.3% |
| Q2 2014 | $638,000 | -69.5% | 8,092 | -71.0% | 0.01% | -69.0% |
| Q1 2014 | $2,092,000 | -74.5% | 27,886 | -73.8% | 0.03% | -62.8% |
| Q4 2013 | $8,207,000 | +1868.1% | 106,301 | +1666.4% | 0.08% | +1460.0% |
| Q3 2013 | $417,000 | -51.6% | 6,018 | -55.8% | 0.01% | -37.5% |
| Q2 2013 | $861,000 | – | 13,600 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |